292 related articles for article (PubMed ID: 28108026)
1. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study.
Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026
[TBL] [Abstract][Full Text] [Related]
2. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
[TBL] [Abstract][Full Text] [Related]
3. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.
Huusom LD; Frederiksen K; Høgdall EV; Glud E; Christensen L; Høgdall CK; Blaakaer J; Kjaer SK
Cancer Causes Control; 2006 Aug; 17(6):821-9. PubMed ID: 16783610
[TBL] [Abstract][Full Text] [Related]
4. Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.
Hannibal CG; Dehlendorff C; Kjaer SK
Gynecol Oncol; 2018 Dec; 151(3):513-518. PubMed ID: 30249529
[TBL] [Abstract][Full Text] [Related]
5. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study.
Madsen C; Baandrup L; Dehlendorff C; Kjaer SK
Acta Obstet Gynecol Scand; 2015 Jan; 94(1):86-94. PubMed ID: 25256594
[TBL] [Abstract][Full Text] [Related]
6. Anthropometry and the risk of epithelial ovarian cancer.
Greer JB; Modugno F; Ness RB; Allen GO
Cancer; 2006 May; 106(10):2247-57. PubMed ID: 16596653
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
[TBL] [Abstract][Full Text] [Related]
8. Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
Stewart LM; Stewart CJR; Spilsbury K; Cohen PA; Jordan S
Gynecol Oncol; 2020 Mar; 156(3):611-615. PubMed ID: 31983516
[TBL] [Abstract][Full Text] [Related]
9. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
10. Parity, contraception, infertility, and the risk of epithelial ovarian cancer.
Risch HA; Marrett LD; Howe GR
Am J Epidemiol; 1994 Oct; 140(7):585-97. PubMed ID: 7942759
[TBL] [Abstract][Full Text] [Related]
11. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones.
Harlow BL; Weiss NS; Roth GJ; Chu J; Daling JR
Cancer Res; 1988 Oct; 48(20):5849-52. PubMed ID: 3167840
[TBL] [Abstract][Full Text] [Related]
12. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Baandrup L
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for epithelial ovarian tumours of borderline malignancy.
Parazzini F; Restelli C; La Vecchia C; Negri E; Chiari S; Maggi R; Mangioni C
Int J Epidemiol; 1991 Dec; 20(4):871-7. PubMed ID: 1800425
[TBL] [Abstract][Full Text] [Related]
14. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.
Lessard-Anderson CR; Handlogten KS; Molitor RJ; Dowdy SC; Cliby WA; Weaver AL; Sauver JS; Bakkum-Gamez JN
Gynecol Oncol; 2014 Dec; 135(3):423-7. PubMed ID: 25316178
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for benign serous and mucinous epithelial ovarian tumors.
Jordan SJ; Green AC; Whiteman DC; Webb PM
Obstet Gynecol; 2007 Mar; 109(3):647-54. PubMed ID: 17329516
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
Kim SJ; Rosen B; Fan I; Ivanova A; McLaughlin JR; Risch H; Narod SA; Kotsopoulos J
Br J Cancer; 2017 Mar; 116(7):964-971. PubMed ID: 28208158
[TBL] [Abstract][Full Text] [Related]
17. Anti-Mullerian hormone and risk of invasive serous ovarian cancer.
Schock H; Lundin E; Vääräsmäki M; Grankvist K; Fry A; Dorgan JF; Pukkala E; Lehtinen M; Surcel HM; Lukanova A
Cancer Causes Control; 2014 May; 25(5):583-9. PubMed ID: 24562905
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Weiderpass E; Persson IR
J Natl Cancer Inst; 2002 Apr; 94(7):497-504. PubMed ID: 11929950
[TBL] [Abstract][Full Text] [Related]
19. Ovarian stimulation and borderline ovarian tumors: a case-control study.
Mosgaard BJ; Lidegaard O; Kjaer SK; Schou G; Andersen AN
Fertil Steril; 1998 Dec; 70(6):1049-55. PubMed ID: 9848294
[TBL] [Abstract][Full Text] [Related]
20. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kjaerbye-Thygesen A; Andersen KK; Tabor A; Kurman RJ; Kjaer SK
Gynecol Oncol; 2014 Aug; 134(2):267-73. PubMed ID: 24924123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
